NCT02270723

Brief Summary

In a randomized clinical trial, the purpose is to investigate if perioperative coagulation and hemorrhage is influenced by colloid or crystalloid.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Aug 2014

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 27, 2014

Completed
24 days until next milestone

First Posted

Study publicly available on registry

October 21, 2014

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2015

Completed
Last Updated

October 21, 2014

Status Verified

October 1, 2014

Enrollment Period

1 year

First QC Date

September 27, 2014

Last Update Submit

October 17, 2014

Conditions

Outcome Measures

Primary Outcomes (1)

  • Measurement of coagulation during surgery and in the recovery room

    Changes in fibrinogen, platelets, hemoglobin, alpha angle and maximum amplitude

    up to 1 day after surgery

Secondary Outcomes (2)

  • Measurement of postoperative surgical complications

    From date of operation up to 1 months postoperatvely

  • Measurement of hemorrhage and use of blood products during anesthesia and in the recovery room

    up to 1 day after surgery

Study Arms (2)

Human Albumin " Behring"

ACTIVE COMPARATOR

Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours

Drug: 5% Human Albumin " Behring"

Lactated Ringer

PLACEBO COMPARATOR

Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours

Drug: Lactated Ringer

Interventions

Intravenous infusion of 5% Human Albumin during major surgery

Also known as: Human Albumin
Human Albumin " Behring"

Intravenous infusion of Lactated Ringer during major surgery

Also known as: Ringer
Lactated Ringer

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient more than 18 years old
  • Indication for elective post-renal operation including cystectomy
  • Patient without anticoagulative, acetylsalicylic acid or nonsteroidal antiinflammatory drug
  • treatment for the last 5 days

You may not qualify if:

  • Intracerebral bleeding, manifest cardiac insufficient, renal insufficient demanding dialysis, hepatic or coagulation diseases
  • Pregnant or nursing
  • Allergic to Human Albumin
  • Disturbance in electrolytes
  • Patient under committee
  • Patient joining another trial interfering the actual trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rigshospitalet

Copenhagen, 2100, Denmark

Location

Related Publications (1)

  • Rasmussen KC, Hojskov M, Johansson PI, Kridina I, Kistorp T, Salling L, Nielsen HB, Ruhnau B, Pedersen T, Secher NH. Impact of Albumin on Coagulation Competence and Hemorrhage During Major Surgery: A Randomized Controlled Trial. Medicine (Baltimore). 2016 Mar;95(9):e2720. doi: 10.1097/MD.0000000000002720.

MeSH Terms

Conditions

HemorrhageHemostatic Disorders

Interventions

Serum Albumin, HumanRinger's Lactate

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsVascular DiseasesCardiovascular DiseasesHemorrhagic DisordersHematologic DiseasesHemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Serum AlbuminAlbuminsProteinsAmino Acids, Peptides, and ProteinsBlood ProteinsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Niels H Secher, MD PHD Prof

    Rigshospitalet, University of Copenhagen

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
MD, Specialist in Surgery

Study Record Dates

First Submitted

September 27, 2014

First Posted

October 21, 2014

Study Start

August 1, 2014

Primary Completion

August 1, 2015

Study Completion

November 1, 2015

Last Updated

October 21, 2014

Record last verified: 2014-10

Locations